
The Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 12, 2024
Reports have described SARS-CoV-2 rebound in COVID-19 patients treated with nirmatrelvir, a 3CL protease inhibitor. The cause remains mystery, although drug resistance, re-infection, and lack of adequate immune responses been excluded. We now present virologic findings that provide clue to the viral rebound, which occurs ∼20% cases. Persistence infectious was experimentally documented vitro after treatment nirmatrelvir or another inhibitor, but not polymerase remdesivir. This form decayed slowly half-life ∼1 day, suggesting its persistence could outlive course re-ignite infection as is eliminated. Notably, extending beyond 8 days abolished vitro. Our point particular direction for future investigation virus offer specific recommendation should be tested clinically.
Language: Английский